HRMY
Harmony Biosciences Holdings, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
10.11
PEG
1.11
P/B
1.84
P/S
1.85
EV/EBITDA
4.34
DCF Value
$126.15
FCF Yield
21.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.2%
Operating Margin
24.0%
Net Margin
18.3%
ROE
19.8%
ROA
13.4%
ROIC
13.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $243.8M | $22.5M | $0.38 |
| FY 2025 | $868.5M | $158.7M | $2.71 |
| Q3 2025 | $239.5M | $50.9M | $0.87 |
| Q2 2025 | $200.5M | $39.8M | $0.68 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.89
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.